International Journal of Stem Cells : eISSN 2005-5447

Table. 1.

Table. 1.

Patients characteristics (n=70)

VariablesNumber(%)Mean±SDMedianMinMax
Age (n=70)32.3±11331862
Gender (n=70)
 Male4361.4%
 Female2738.6%
Medical diagnosis (n=69)
 Nonmalignant1928%
 Malignant5072%
HSCT type (n=70)
 Auto2738.6%
 Allo4361.4%
Donor gender (n=44)
 Male3477%
 Female1023%
Event-free survival (n=41)
 No event recorded1946%
 With event of complication2254%
Death (n=49)
 No3367%
 Yes1633 %
AKI based on RIFLE criteria (n=60)
 No AKI4168.3%
 Risk813.3%
 Injury915%
 Failure23.3%
Body mass Index (BMI) (n=64)25.8±5.425.717.445.8
Body Surface area (BSAm2) (n=64)1.77±0.91.721.42.0
Blood urea nitrogen (BUN)34.9±2727.27.5170
Conditioning therapy
 Cyclophosphamide 50–60 mg/kg+Fludarabine 68.6%
  30~35 mg/m2±ATG 3 mg/kg
 Melphalan 180 mg/m22941.4%
 Melphalan 80~130 mg/m2+Fludarabine 30~35 mg/m21115.7%
 Melphalan 180 mg/m2+VP-16 700~1200 mg OR 1521.4%
  Fludarabine 90~150 mg
 Other (miscellaneous912.9%
International Journal of Stem Cells 2019;12:43-50 https://doi.org/10.15283/ijsc18056
© 2019 International Journal of Stem Cells